In the News
Listen to Dr. Phumla Sinxadi and others talk on the cost of curing disease here.
The local South African government released a press statement on World Malaria Day 2016 describing the current local and international thinking on Malaria. Read the press statement here .
UCT's H3D Partners with Janssen Pharmaceutical Companies to Advance Drug Development in Africa. Read more about the partnership here
Strength in standardisation: developing CDISC standards for malaria. “We are now at the forefront of developing a data standard for the malaria research community. The aim of this initiative is to support the efficient, scientifically valid, generation and reporting of malaria clinical data, and to conform to regulatory requirements for registration of new antimalarial compounds,” says Lesley Workman, Coordinator of the WWARN Pharmacology Group who is leading on the CDISC project. Read more
Evidence to inform equitable dosing in very young and malnourished children.
Our research provides health workers and researchers with an improved definition of the day 7 lumefantrine concentration threshold, which will help them to understand if treatment failure is caused by drug resistant malaria parasites or by inadequate drug concentrations, " Professor Karen Barnes (UCT). Visit http://www.wwarn.org/news for more information.
CLINICAL DRUG TRIALS: Tests of progress. The Financial Mail reported on the launch of the UCT Clinical Research Centre's phase one unit in the article Professor Barnes, discusses the need for close monitoring during phase 1 studies "It is a complex science to move safely and responsibly from animal and test tube studies to studies in people. We start with very low doses in small numbers of healthy people and watch them closely. If that goes well, we give slightly more, gradually building up until we get past the dose that we guess will be effective," Read the full article here